Day: February 26, 2026

SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) — Kura Oncology, Inc. (Nasdaq: KURA), a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced it will report fourth quarter and full year 2025 financial results on Thursday, March 5, 2026, before the U.S. financial markets open. Kura’s management will host a conference call and webcast at 8:00 a.m. ET / 5:00 a.m. PT to discuss the financial results and provide a corporate update. The live webcast and archived replay of the event may be accessed on the Investors section of the Company’s website at www.kuraoncology.com. About Kura Oncology Kura Oncology is a biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. Kura’s pipeline of small molecule drug candidates...

GAITHERSBURG, Md., Feb. 26, 2026 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, today announced that it will report its fourth quarter 2025 financial results on Thursday, March 5, 2026. Altimmune management will host a conference call at 8:30 a.m. ET on March 5 to discuss the financial results and provide a business update. The conference call will be webcast live on Altimmune’s Investor Relations website at https://ir.altimmune.com/investors. Participants who would like to join the call may register here to receive dial-in numbers and a unique PIN. A replay will be available on the Investor Relations website shortly after the call for up to three months. About AltimmuneAltimmune is a late clinical-stage biopharmaceutical...

Figure 1MD Projects-Eeyou Istchee James BayFigure 2Caniaspic Au 2025 ResultsFigure 3Caniapisc Au Planned IPFigure 4Samples 2025Figure 5Samples 2025Figure 6Samples 2025MONTREAL, Feb. 26, 2026 (GLOBE NEWSWIRE) — Midland Exploration Inc. (“Midland”) (TSX-V: MD) is pleased to announce the start of an induced polarization ground (“IP’) geophysical survey on its Caniapisc Au project, in the Eeyou Istchee James Bay and Caniapiscau regions. The Caniapisc Au project is wholly owned by Midland and consists of 315 exclusive exploration rights (“EER”) covering an area of 159 square kilometres. Highlights:The 2025 exploration programs successfully identified several gold-bearing boulders, with a maximum value of 24.5 g/t Au on a selected boulder grab sample (see press release by Midland...

HOLLISTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) — Harvard Bioscience, Inc. (Nasdaq: HBIO) will announce its financial results for the quarter ended December 31, 2025, before the market opens on March 12, 2026, and will hold a conference call to discuss the results at 8:00 a.m. Eastern Time.  Participants who would like to join the call and ask a question must register here. Once registered, you will receive the dial-in numbers and a unique PIN number.  Participants who would like to join the audio-only webcast should go to our events and presentations on the investor website here. Financial information presented on the call, including the earnings release and a related slide presentation, will be available on the Investor Relations section of Harvard Bioscience’s website.  About Harvard Bioscience  Harvard Bioscience, Inc. is...

TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) — Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the timing of its Premarket Approval (“PMA”) submission to the U.S. Food and Drug Administration (“FDA”) for its hemoadsorption device to treat endotoxic septic shock. Following recent interaction with the FDA, the Company now expects to submit its PMA around the end of April to mid-May 2026, compared to its previously disclosed target of Q1 2026. The updated timing reflects ongoing FDA feedback to incorporate complete 12-month mortality data from the Tigris study into the PMA submission, as well as the completion of certain non-clinical module items, including human factors engineering testing, to support...

HAELO Phase 3 clinical data for lonvo-z in HAE expected by mid-2026; BLA submission in second half of 2026; anticipated U.S. launch in first half of 2027 Process underway to reactivate global sites for MAGNITUDE-2 Phase 3 clinical trial of nex-z in ATTRv-PN; enrollment completion expected in second half of 2026 FDA engagement ongoing to resolve clinical hold on MAGNITUDE Phase 3 clinical trial of nex-z in ATTR-CM Ended 2025 with approximately $605 million in cash, cash equivalents and marketable securities; expected to fund operations into the second half of 2027CAMBRIDGE, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today reported business updates and financial...

– Generated Quarterly Net Revenues of $205.4 Million, Up 13% Year-over-Year, and Record Full-Year Net Revenues of $780.6 Million, Up 24% Year-over-Year – – Generated Record Quarterly and Full-Year Jornay PM® Net Revenue of $45.9 Million and $148.9 Million, Up 57% and 48%, Respectively, Year-over-Year – – Generated Quarterly Pain Portfolio Net Revenues of $159.6 Million, Up 5% Year-over-Year, and Record Full-Year Pain Portfolio Net Revenues $631.7 Million, Up 6% Year-over-Year – – Ended 2025 with Cash, Cash Equivalents, and Marketable Securities of $386.7 Million – – Reaffirmed Full-Year 2026 Guidance – – Conference Call Scheduled for Today at 8:00 a.m. ET – STOUGHTON, Mass., Feb. 26, 2026 (GLOBE NEWSWIRE) — Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today reported its financial results for the quarter and full year ended December...

Two decades of global service excellence underscore Colliers’ commitment to client success TORONTO, Feb. 26, 2026 (GLOBE NEWSWIRE) — Colliers (NASDAQ, TSX: CIGI), a leading diversified professional services and investment management company, has been named to the 2026 Global 100 list produced by IAOP® in the Leader category for large, established global firms. This marks the 20th consecutive year that Colliers has been recognized for global service excellence. IAOP’s annual list recognizes the world’s top outsourcing service providers and advisors based on rigorous evaluation criteria, including customer references, awards and certifications, programs for innovation, and corporate social responsibility. The IAOP Global 100 serves as a trusted resource for organizations seeking high-performing partners across a broad range of outsourcing...